Hinojosa-Gonzalez David E, Somani Bhaskar, Olvera-Posada Daniel, Segall Michal, Villanueva-Congote Juliana, Eisner Brian H
Scott Department of Urology, Baylor College of Medicine, Houston, TX, United States.
University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Can Urol Assoc J. 2024 Sep;18(9):E285-E290. doi: 10.5489/cuaj.8721.
Percutaneous nephrolithotomy (PCNL) is the gold-standard treatment for large renal stones. One potentially significant complication of PCNL is blood loss, which can result in transfusion requirement and poorer stone-free outcomes. Tranexamic acid (TXA) has emerged as a promising intervention, administered systemically (TXA-S) or as part of irrigation fluid (TXA-I) in endourology. This study aimed to comprehensively analyze existing evidence regarding the applications of TXA in PCNL through a Bayesian network meta-analysis, offering insights into its efficacy and comparative effectiveness.
In February 2022, a PRISMA-compliant systematic review (PROSPERO registration number CRD 42021270593) was performed to identify randomized controlled clinical trials (RCT) on TXA as either systemic therapy or in irrigation fluid. Studies in languages other than English and Spanish were not considered. A Bayesian network was built using results from identified studies to create models that were later run through Markov Chain Monte Carlo sampling through 200 000 iterations.
Eight RCTs compared TXA-S vs. placebo, one TXA-I vs. placebo, and one TXA-I vs. TXA-S. TXA-I had lower risk of transfusion (relative risk [RR] 0.63 [0.47,0.84], SUCRA 0.950) than TXA-S (RR 0.79 [0.65,0.95], SUCRA 0.545). TXA-I had a lower risk of complications (RR 0.38 [0.21,0.67], SUCRA=0.957) compared to TXA-S (RR 0.55 [0.39, 0.78], SUCRA 0.539). TXA-I had a lower postoperative decrease in hemoglobin (mean difference [MD] -1.2 [1.3, 1.0], SUCRA 0.849) compared to TXA-S (MD -0.97 [-1.0, -0.93], SUCRA 0.646]).
TXA, regardless of the route of administration, is an effective intervention in decreasing bleeding, postoperative complications, and risk of transfusion when compared with placebo. Further studies directly comparing TXA-S to TXA-I would be useful to determine the optimal route of delivery.
经皮肾镜取石术(PCNL)是治疗大型肾结石的金标准疗法。PCNL一种潜在的重大并发症是失血,这可能导致需要输血,并降低结石清除率。氨甲环酸(TXA)已成为一种有前景的干预措施,在内镜泌尿外科中可全身给药(TXA-S)或作为冲洗液的一部分(TXA-I)。本研究旨在通过贝叶斯网络荟萃分析全面分析有关TXA在PCNL中应用的现有证据,以深入了解其疗效和相对有效性。
2022年2月,我们进行了一项符合PRISMA标准的系统评价(PROSPERO注册号CRD 42021270593),以确定关于TXA作为全身治疗或冲洗液的随机对照临床试验(RCT)。不考虑非英语和西班牙语的研究。利用纳入研究的结果构建贝叶斯网络,创建模型,随后通过马尔可夫链蒙特卡罗抽样进行200000次迭代运行。
八项RCT比较了TXA-S与安慰剂,一项比较了TXA-I与安慰剂,一项比较了TXA-I与TXA-S。与TXA-S(相对风险[RR]0.79[0.65,0.95],累积排序曲线下面积[SUCRA]0.545)相比,TXA-I的输血风险较低(RR 0.63[0.47,0.84],SUCRA 0.950)。与TXA-S(RR 0.55[0.39,0.78],SUCRA 0.539)相比,TXA-I的并发症风险较低(RR 0.38[0.21,0.67],SUCRA=0.957)。与TXA-S(平均差[MD]-0.97[-1.0,-0.93],SUCRA 0.646)相比,TXA-I术后血红蛋白下降幅度较小(MD -1.2[1.3,1.0],SUCRA 0.849)。
与安慰剂相比,无论给药途径如何,TXA都是一种有效减少出血、术后并发症和输血风险的干预措施。进一步直接比较TXA-S和TXA-I的研究将有助于确定最佳给药途径。